Literature DB >> 2105994

Effects of combinations of transforming growth factor-beta 1 and tumor necrosis factor on induction of differentiation of human myelogenous leukemic cell lines.

R Kamijo1, K Takeda, M Nagumo, K Konno.   

Abstract

Effects of transforming growth factor-beta 1 (TGF-beta 1), either alone or in combination with TNF, on the induction of differentiation of human myelogenous leukemic cell lines were examined. TGF-beta 1 alone induced differentiation of a human monocytic leukemia U-937 line into the cells with macrophage characteristics. When combined with TNF, TGF-beta 1 synergistically or additively induced differentiation associated properties. A human myeloblastic leukemia cell line, ML-1, differently responded to TGF-beta 1 in induction of differentiation. FcR activity and phagocytic activity induced by TNF were suppressed by TGF-beta 1. However, nitroblue tetrazolium reducing activity was synergistically induced by combinations of TGF-beta 1 and TNF. Scatchard analysis of TNF receptors indicated that the number of binding sites and dissociation constant of TNF for its receptors on U-937 or ML-1 cells were not changed by treatment with TGF-beta 1. Although IFN-gamma, IL-6, granulocyte CSF, and granulocyte-macrophage CSF-induced nitroblue tetrazolium reducing activity of U-937 cells, only IFN-gamma, and TNF induced it synergistically in combination with TGF-beta 1. Synergism between TGF-beta 1 and TNF was also observed in inhibition of growth of U-937 and ML-1 cells. Although TGF-beta 1 induction of differentiation of other monocytoid leukemic THP-1 cells was similar to that of U-937 cells, TGF-beta 1 only slightly induced differentiation of promyelocytic leukemic HL-60 cells, either alone or in combination with TNF. Our observations indicate that TGF-beta 1 strongly modulates differentiation and proliferation of human myelogenous leukemia cells, macrophage precursors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2105994

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Differentiation therapy of leukemia: 3 decades of development.

Authors:  Daniel Nowak; Daphne Stewart; H Phillip Koeffler
Journal:  Blood       Date:  2009-02-12       Impact factor: 22.113

2.  Regulation of c-fgr messenger RNA levels in U937 cells treated with different modulating agents.

Authors:  L Faulkner; M Patel; P M Brickell; D R Katz
Journal:  Immunology       Date:  1992-05       Impact factor: 7.397

3.  Increasing infiltration and activation of CD8+ tumor-infiltrating lymphocytes after eliminating immune suppressive granulocyte/macrophage progenitor cells with low doses of interferon gamma plus tumor necrosis factor alpha.

Authors:  M R Young; G McCloskey; M A Wright; A S Pak
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

4.  Transforming growth factor-beta regulates human retinal pigment epithelial cell phagocytosis by influencing a protein kinase C-dependent pathway.

Authors:  S J Sheu; T Sakamoto; R Osusky; H M Wang; T E Ogden; S J Ryan; D R Hinton; R Gopalakrishna
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-11       Impact factor: 3.117

5.  Synergistic effect of IL-4 and TNF-alpha in the induction of monocytic differentiation of a mouse myeloid leukaemic cell line (WEHI-3B JCS).

Authors:  K N Leung; N K Mak; M C Fung; A J Hapel
Journal:  Immunology       Date:  1994-01       Impact factor: 7.397

6.  Transforming growth factor beta 1 and gamma interferon provide opposing signals to lipopolysaccharide-activated mouse macrophages.

Authors:  E H Hausmann; S Y Hao; J L Pace; M J Parmely
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

7.  LRRC33 is a novel binding and potential regulating protein of TGF-β1 function in human acute myeloid leukemia cells.

Authors:  Wenjiang Ma; Yan Qin; Bjoern Chapuy; Chafen Lu
Journal:  PLoS One       Date:  2019-10-10       Impact factor: 3.240

8.  Allium compounds, dipropyl and dimethyl thiosulfinates as antiproliferative and differentiating agents of human acute myeloid leukemia cell lines.

Authors:  Faten Merhi; Jacques Auger; Francine Rendu; Brigitte Bauvois
Journal:  Biologics       Date:  2008-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.